April 2026 Veradermics advanced its extended-release oral hair-loss candidate VDPHL01 after a Phase 2/3 study demonstrated positive outcomes in male pattern hair loss, supporting continued late-stage development of a potential oral treatment for androgenetic alopecia.
December 2025 Cosmo Pharmaceuticals announced positive Phase III topline results from the SCALP 1 and SCALP 2 studies of clascoterone 5% solution for male androgenetic alopecia and initiated regulatory submission activities in the U.S. and Europe.
September 2025 MedPark Hospital opened a dedicated Hair Restoration Center in Thailand in collaboration with hair transplantation specialist Dr. Damkerng Pathomvanich. The center expanded hospital-based hair restoration services with FUE, FUT, and combined transplantation procedures.
July 2025 Sun Pharmaceutical Industries launched LEQSELVI (deuruxolitinib) 8 mg tablets across the United States for adults with severe alopecia areata, expanding its dermatology and hair-loss treatment portfolio.